Assessment of Some Adepocytokines in Obese Males
DOI:
https://doi.org/10.52783/jns.v14.4146Keywords:
Obesity, BMI, WHR, NOW, WCAbstract
Obesity metrics are essential for assessing health risks and formulating effective preventive and therapeutic strategies. The study aimed to investigate various obesity-related proteins, including ET-01, Nesfatin-1, Vaspin, Visfatin, Ghrelin, Apelin, Leptin, and Resistin, in obese persons and healthy controls.
A total of 160 people (120 obese patients and 40 controls) participated in the study from January 2024 to June 2024. The samples underwent centrifugation (3000 g, 20 min.), after which the serum was isolated and stored at -20°C. Serum from both the patient and control groups was subjected to enzyme-linked immunosorbent assay (ELISA) assays for ET-01, Nesfatin-1, Vaspin, Visfatin, Ghrelin, Apelin, Leptin, and Resistin. The present study included 160 participants across various stages of obesity and age groups, ranging from 19 to 55 years, with a mean age of 31 years for overweight individuals, 39 years for type I obese, 46 years for type II obese, and 24 years for the control group, respectively. The biomarkers of obesity were evaluated in the study population, revealing a significant difference in Aplin levels with P<0.05; the mean Aplin level was lowest in the obese type II group (77.6 pg/dl). The other obesity biomarkers showed no significant differences across the research groups, with almost all exhibiting P>0.05. The current investigation demonstrated no significant correlation between obesity indicators and weight gain, despite a notable increase in serum Apelin levels in obese subjects.
Downloads
Metrics
References
K. K. Panuganti, M. Nguyen, R. K. Kshirsagar, and C. Doerr, “Obesity (nursing),” 2021.
M. Al Hariri, H. Al‐Sulaiti, N. Anwardeen, K. Naja, and M. A. Elrayess, “Comparing the metabolic signatures of obesity defined by waist circumference, waist‐hip ratio, or BMI,” Obesity, vol. 32, no. 8, pp. 1494–1507, 2024.
M. Blüher, “Obesity: global epidemiology and pathogenesis,” Nat. Rev. Endocrinol., vol. 15, no. 5, pp. 288–298, 2019.
J. B. Dixon, “The effect of obesity on health outcomes,” Mol. Cell. Endocrinol., vol. 316, no. 2, pp. 104–108, 2010.
A. De Lorenzo, R. Martinoli, F. Vaia, and L. Di Renzo, “Normal weight obese (NWO) women: an evaluation of a candidate new syndrome.,” Nutr. Metab. Cardiovasc. Dis., vol. 16, no. 8, pp. 513–523, Dec. 2006, doi: 10.1016/j.numecd.2005.10.010.
A. S. Olafsdottir, J. E. Torfadottir, and S. A. Arngrimsson, “Health behavior and metabolic risk factors associated with normal weight obesity in adolescents,” PLoS One, vol. 11, no. 8, p. e0161451, 2016.
A. Booth, A. Magnuson, J. Fouts, and M. T. Foster, “Adipose tissue: an endocrine organ playing a role in metabolic regulation,” Horm. Mol. Biol. Clin. Investig., vol. 26, no. 1, pp. 25–42, 2016.
K. Smitka and D. Marešová, “Adipose tissue as an endocrine organ: an update on pro-inflammatory and anti-inflammatory microenvironment,” Prague Med. Rep., vol. 116, no. 2, pp. 87–111, 2015.
A. A. Ahmood, M. J. Mohammed, and M. M. Taha, “Alterations in Immune Parameters ADP , ANA , IL-1 , IL-6 , IL-8 , STAT-4 , and TNF Alpha in Patients with Rheumatoid Arthritis and Osteoarthritis,” pp. 104–120, 2024.
S. Schnyder and C. Handschin, “Skeletal muscle as an endocrine organ: PGC-1α, myokines and exercise,” Bone, vol. 80, pp. 115–125, 2015.
H. S. Chung and K. M. Choi, “Adipokines and myokines: a pivotal role in metabolic and cardiovascular disorders,” Curr. Med. Chem., vol. 25, no. 20, pp. 2401–2415, 2018.
K.-J. Oh, D. S. Lee, W. K. Kim, B. S. Han, S. C. Lee, and K.-H. Bae, “Metabolic adaptation in obesity and type II diabetes: myokines, adipokines and hepatokines,” Int. J. Mol. Sci., vol. 18, no. 1, p. 8, 2016.
F. D. Oleiwi, M. J. Mohammed, and C. I. Ali, “The Relationship of CXCL12 with Sperm Agglutination and Anti-Sperm Antibody Among Infertile Men,” Adv. Life Sci., vol. 11, no. 4, pp. 785–790, 2024, doi: 10.62940/als.v11i4.2552.
I. Lingvay, R. V Cohen, C. W. le Roux, and P. Sumithran, “Obesity in adults,” Lancet, vol. 404, no. 10456, pp. 972–987, 2024.
A. T. Andreacchi et al., “Body mass index, waist circumference, waist-to-hip ratio, and body fat in relation to health care use in the Canadian Longitudinal Study on Aging,” Int. J. Obes., vol. 45, no. 3, pp. 666–676, 2021, doi: 10.1038/s41366-020-00731-z.
C. Li et al., “The Role of Apelin-APJ System in Diabetes and Obesity.,” Front. Endocrinol. (Lausanne)., vol. 13, p. 820002, 2022, doi: 10.3389/fendo.2022.820002.
Ł. Pilarski, M. Pelczyńska, A. Koperska, A. Seraszek-Jaros, M. Szulińska, and P. Bogdański, “Association of Serum Vaspin Concentration with Metabolic Disorders in Obese Individuals.,” Biomolecules, vol. 13, no. 3, Mar. 2023, doi: 10.3390/biom13030508.
A. Y. Soeroto et al., “Effect of increased BMI and obesity on the outcome of COVID-19 adult patients: A systematic review and meta-analysis,” Diabetes Metab. Syndr. Clin. Res. Rev., vol. 14, no. 6, pp. 1897–1904, 2020.
B. R. Weil, C. M. Westby, G. P. Van Guilder, J. J. Greiner, B. L. Stauffer, and C. A. DeSouza, “Enhanced endothelin-1 system activity with overweight and obesity.,” Am. J. Physiol. Heart Circ. Physiol., vol. 301, no. 3, pp. H689-95, Sep. 2011, doi: 10.1152/ajpheart.00206.2011.
I. K. I. Al-Yassiri, F. J. Al-Tu’ma, M. A. Mukheef, K. B. Jawad, and B. A.-K. Mutar, “Association between Nesfatin-1 Levels and C-Peptide in Sera of Obese/Non-Obese Type 2 Diabetic Women.,” J. Contemp. Med. Sci., vol. 9, no. 1, 2023.
A. A. Ahmood, M. J. Mohammed, and M. M. Taha, “Alterations in Physiological Parameters Osteocalcin , Osteonectin , Osteopontin , Vitamin D , Vaspin and Visfatin in Rheumatoid Arthritis and Osteoarthritis Patients,” vol. 6, pp. 5960–5985, 2024, doi: 10.48047/AFJBS.6.Si4.2024.
Y. Lv, T. Liang, G. Wang, and Z. Li, “Ghrelin, a gastrointestinal hormone, regulates energy balance and lipid metabolism.,” Biosci. Rep., vol. 38, no. 5, Oct. 2018, doi: 10.1042/BSR20181061.
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
You are free to:
- Share — copy and redistribute the material in any medium or format
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
Terms:
- Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
